Fundraising Fox
/Companies
Sign in

Amporin

Basel, CH · 2 known investors

Find your way into Amporin

Each arrow is one introduction. Sign up to fill in the first one.

1,145 people can intro you to Kelvin

Ask Dr Stewart Washer to introduce you to Kelvin Stott

You →Dr · together at Inventages Venture Capital →Kelvin

136 people can intro you to Hervé

Ask Jamie Chen to introduce you to Hervé Schaffhauser

You →Jamie · together at Coave Therapeutics →Hervé

126 people can intro you to Daniel

Ask Sam Okafor to introduce you to Daniel Umbricht

You →Sam · together at Gilgamesh Pharma →Daniel

Sign up to find every way you can get introduced to Amporin

  • Your email: who you already know at Amporin, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Amporin team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sign up with GoogleAlready have an account? Log in

Amporin Pharmaceuticals develops small-molecule drugs targeting toxic membrane pores formed by misfolded protein oligomers to treat neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, and Type 2 diabetes. The company aims to slow or halt disease progression and enable functional recovery in patients with protein misfolding and aggregation disorders.

AI & Machine LearningBiotechDeep Tech

Founders & leadership

KSKelvin Stott
Kelvin StottCEO and CofounderKelvin Stott brings over 25 years of experience in pharmaceutical R&D strategy, drug discovery and development, portfolio management, and business operations across biotech startups and venture capital. He holds expertise in innovation and performance management, having worked in strategy consulting and led multiple drug development programs.
HSHervé Schaffhauser
Hervé SchaffhauserCSO and CofounderHervé Schaffhauser is a neuropharmacologist with over 20 years of drug development experience spanning target validation, preclinical studies, and Phase 1 clinical trials across pharmaceutical companies and startups. He has contributed to regulatory submissions and led preclinical programs involving small-molecule and large-molecule therapeutics including mRNA and AAV-based approaches.
DUDaniel Umbricht
Daniel UmbrichtCMO and CofounderHe has expertise in early clinical development, translational neuroscience, electrophysiology, and clinical research methodology, with prior work in schizophrenia and mood disorder research.

Investors · 2

Venture KickreportedSchlieren-Zürich

How we know: funding news · press coverage · Not right? Tell us

Frequently asked questions

What does Amporin do?
Amporin Pharmaceuticals develops small-molecule drugs targeting toxic membrane pores formed by misfolded protein oligomers to treat neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, and Type 2 diabetes. The company aims to slow or halt disease progression and enable functional recovery in patients with protein misfolding and aggregation disorders.
Who founded Amporin?
Amporin was founded by Kelvin Stott, Hervé Schaffhauser, Daniel Umbricht.
Who are Amporin's investors?
Amporin's investors include Kickfund, Venture Kick.
Where is Amporin headquartered?
Amporin is headquartered in Basel, CH.